Evidence map›Paper›PMID 37321843›Full record

ArticleSexually transmitted infections2023

Predictors of starting and stopping chemsex in men who have sex with men in England: findings from the AURAH2 prospective study.

Robbie Hammond, Valentina Cambiano, Fiona C Lampe, David Asboe, Amanda Clarke, Richard Gilson, Graham J Hart, Ada Rose Miltz, Nneka Nwokolo, Anne M Johnson and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Sexually transmitted infections, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Robbie HammondDepartment of Infectious Diseases, Royal Free London NHS Foundation Trust, London, UK robert.hammond1@nhs.net.
Valentina CambianoInstitute for Global Health, University College London, London, UK.
Fiona C LampeInstitute for Global Health, University College London, London, UK.
David AsboeSt Stephen's Centre, Chelsea and Westminster Healthcare NHS Trust, London, UK.
Amanda ClarkeDepartment of Sexual Health, University Hospitals Sussex NHS Foundation Trust, Worthing, UK.
Richard GilsonInstitute for Global Health, University College London, London, UK.ORCID 0000-0002-9572-193X
Graham J HartInstitute for Global Health, University College London, London, UK.
Ada Rose MiltzInstitute for Global Health, University College London, London, UK.ORCID 0000-0003-2771-7880
Nneka NwokoloSt Stephen's Centre, Chelsea and Westminster Healthcare NHS Trust, London, UK.
Anne M JohnsonInstitute for Global Health, University College London, London, UK.
Andrew N PhillipsInstitute for Global Health, University College London, London, UK.
Andrew SpeakmanInstitute for Global Health, University College London, London, UK.
Gary Whitlock56 Dean Street, Chelsea and Westminster Healthcare NHS Trust, London, UK.
Alison RodgerDepartment of Infectious Diseases, Royal Free London NHS Foundation Trust, London, UK.
Janey SewellInstitute for Global Health, University College London, London, UK.ORCID 0000-0001-7148-2391
University College London · GBRoyal Free London NHS Foundation Trust · GBSouth London Healthcare NHS Trust · GBUniversity Hospitals Sussex NHS Foundation Trust · GB

Funding

Department of Health RP-PG-1212-20006
6 · The paper itself

Abstract

backgroundChemsex (the use of psychoactive drugs in sexual contexts) has been associated with HIV acquisition and other STIs, so there is benefit in identifying those most likely to start chemsex to offer risk reduction interventions such as pre-exposure prophylaxis (PrEP). To date, there have been no data from a longitudinal study analysing factors most associated with starting and stopping chemsex.

methodsThe prospective cohort study, Attitudes to and Understanding Risk of Acquisition of HIV over Time (AURAH2), collected 4 monthly and annual online questionnaire data from men who have sex with men (MSM) from 2015 to 2018. We investigate the association of sociodemographic factors, sexual behaviours and drug use with starting and stopping chemsex among 622 men who completed at least one follow-up questionnaire. Poisson models with generalised estimating equations were used to produce risk ratios (RRs) accounting for multiple starting or stopping episodes from the same individual. Multivariable analysis was adjusted for age group, ethnicity, sexual identity and university education.

findingsIn the multivariable analysis, the under 40 age group was significantly more likely to start chemsex by the next assessment (RR 1.79, 95% CI 1.12 to 2.86). Other factors which showed significant association with starting chemsex were unemployment (RR 2.10, 95% CI 1.02 to 4.35), smoking (RR 2.49, 95% CI 1.63 to 3.79), recent condomless sex (CLS), recent STI and postexposure prophylaxis (PEP) use in the past year (RR 2.10, 95% CI 1.33 to 3.30). Age over 40 (RR 0.71, 95% CI 0.51 to 0.99), CLS, and use of PEP (RR 0.64, 95% CI 0.47 to 0.86) and PrEP (RR 0.47, 95% CI 0.29 to 0.78) were associated with lower likelihood of stopping chemsex by the next assessment.

interpretationKnowledge of these results allows us to identify men most likely to start chemsex, thus providing an opportunity for sexual health services to intervene with a package of risk mitigation measures, especially PrEP use.

Indexed as

HIV InfectionsPre-Exposure ProphylaxisSexual and Gender MinoritiesSexually Transmitted DiseasesEnglandHomosexuality, MaleHumansLongitudinal StudiesMaleProspective StudiesSexual BehaviorSurveys and QuestionnairesDRUG MISUSEHIVHomosexuality, MaleSexual BehaviorSEXUAL HEALTH

Identifiers

PMID37321843
PMCPMC10715473
OpenAlexW4380785505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.